OUR GOAL IS TO BE A LEADER IN THE DEVELOPEMENT OF TARGETED THERAPIES FOR PATIENTS WITH CANCER AND OTHER DISEASES OF HIGH UNMET NEED
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration (“AMD”) and fibrotic diseases. Our lead product candidate, DE-122, is an endoglin antibody that is being developed for the treatment of wet AMD in the randomized Phase 2 AVANTE trial through a collaboration with Santen Pharmaceutical Co., Ltd., a global ophthalmology company who licensed from us exclusive worldwide rights to develop and commercialize our endoglin antibodies for ophthalmology indications. Our other product candidates are TRC102, a small molecule that is in Phase 2 clinical development for the treatment of mesothelioma; TRC253, an small molecule inhibitor of wild type and mutated forms of the androgen receptor that is in Phase 2 clinical development for prostate cancer, that is being developed through a collaboration with Janssen Pharmaceutica N.V.; TJ004309, a CD73 antibody that is expected to begin Phase 1 testing in 2019, that is being developed through a collaboration with I-Mab Biopharma; multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma; and TRC205, an endoglin antibody that is in preclinical development for the treatment of fibrotic diseases.
We operate a clinical development model that emphasizes capital efficiency. Our experienced clinical operations, product development and regulatory affairs groups enable us to eliminate the cost associated with hiring contract research organizations to manage clinical, regulatory and database aspects of our Phase 1, Phase 2 and Phase 3 clinical trials. We have also collaborated with the National Cancer Institute, which selected TRC102 for federal funding of clinical development, as well as Case Western Reserve University.
Charles P. Theuer, President and CEO
Dr. Theuer has served as our President, Chief Executive Officer and a member of our board of directors since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.
Mark Wiggins, Chief Business Officer
Mr. Wiggins joined us as our Chief Business Officer in May 2018. Prior to joining us, served as Senior Vice President of Corporate and Business Development at Elcelyx Therapeutics, and Chief Business Officer at Mpex Pharmaceuticals. Prior to this, he was Executive Vice President of Corporate and Business Development at Biogen Idec, and Vice President of Marketing and Business Development at IDEC Pharmaceuticals. Mr. Wiggins also previously served as Head of U.S. Business Development at Schering-Plough (now Merck), in addition to roles at Pfizer and Johnson & Johnson. Mr. Wiggins currently serves on the board of directors of Zogenix and SelectION. He received a B.S. in finance from Syracuse University and an M.B.A. from the University of Arizona.
Bonne Adams, Executive Vice President
Ms. Adams joined us as our Vice President of Clinical Operations in August 2006, was promoted to Senior Vice President of Clinical Operations in July 2014, and was promoted to Executive Vice President of Clinical Operations in January 2019. Prior to joining us, Ms. Adams was a Manager of Clinical Operations at Pfizer, Inc., a pharmaceutical corporation, from 2004 to 2006 and at Biogen Idec, Inc., a biotechnology company, from 2002 to 2004. Ms. Adams managed clinical trials at Pfizer that contributed to the 2006 approval of Sutent® in renal cell carcinoma and gastrointestinal stromal tumors, and she managed clinical trials at Biogen Idec that fulfilled post-approval commitments for Zevalin® and Rituxan®. Ms. Adams has managed both early and late-stage oncology studies of small molecules as well as biologics in the areas of lymphoma, lung, colorectal, ovarian, kidney, sarcoma and breast cancers. From 2000 to 2002, she managed non-oncology programs at Quintiles Inc., a service provider for biopharmaceutical and health sciences companies, including studies in the areas of allergy and pulmonary disease. Ms. Adams received a B.A. in Kinesiology and Biology from the University of Colorado and an M.B.A. in Technology Management from The University of Phoenix.
Suzy Benedict, Senior Vice President
Ms. Benedict joined us as our Director of Regulatory Affairs in 2007, was promoted to Vice President of Regulatory Affairs in January 2014, and was promoted to Senior Vice President of Regulatory Affairs in January 2019. Ms. Benedict previously held positions in Regulatory Chemistry, Manufacturing and Controls (CMC) at Pfizer, Inc. and Amylin Pharmaceuticals, Inc. At Pfizer, she led the Regulatory CMC activities for the approval of Viracept® Tablets, 625 mg and played a key role in the global approvals for Macugen®. She began her pharmaceutical career at Agouron Pharmaceuticals in Medicinal Chemistry synthesizing VEGF inhibitors. Ms. Benedict has led the Regulatory CMC activities on chemical and pharmaceutical development teams from compound identification through commercialization and has experience with small molecule, peptide, oligonucleotide and protein products spanning a wide range of therapeutic areas. Ms. Benedict received a B.A. from the University of California, Santa Barbara and a M.S. in Chemistry from San Diego State University.
Jennifer Ellis, Head of Quality Assurance
Ms. Ellis has been Head of Quality Assurance at TRACON since August 2014. Prior to joining us, Ms. Ellis was Vice President of Quality Assurance at Trius Therapeutics, Inc. (acquired by Cubist Pharmaceuticals, Inc.) where she led the GxP Quality activities for development and commercialization of SivextroTM. SivextroTM was approved by the U.S Food and Drug Administration in June 2014. She started her career as an analytical chemist at Alliance Pharmaceuticals, then moved to leading analytical and CMC project teams at Pfizer, Inc.. In her career she has led CMC and Quality groups in the development of compounds in a variety of therapeutic areas. Ms. Ellis received a B.A. in Chemistry from the University of Delaware.
Scott B. Brown, Chief Accounting Officer and Head of Finance
Mr. Brown joined us as Director, Finance and Controller in August 2015, was promoted to Sr. Director, Finance and Controller in January 2017, and was promoted to Vice President, Finance and Head of Finance in January 2019. Prior to joining us, Mr. Brown was Associate Director, Finance at Ardea Biosciences (acquired by AstraZeneca) where he led finance and accounting for Ardea Biosciences as a subsidiary of AstraZeneca from 2013 to 2015. Before that, from 2011 to 2013 Mr. Brown was Finance Manager at SciClone Pharmaceuticals, Inc., and Finance Manager at Exelixis, Inc. from 2009 to 2011. Prior to Exelixis, Mr. Brown held accounting positions of increasing responsibility at AcelRx, Inc., Spinal Elements, Inc., Stewart Title, and as an audit associate for KPMG, LLP. Mr. Brown received a B.S. from the University of California, Santa Barbara, a M.S. in Accountancy from San Diego State University, and is a Certified Public Accountant licensed in the state of California.